- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Palisade Bio Inc (PALI)
The Palisade Bio share price today is 1.800, view NASDAQ PALI stock exchange data. Track the latest Palisade Bio share price with real-time updates on PALI stock performance including market cap, day range, 52-week range and dividend yield. Access PALI charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.800
1.990
52 wk Range
0.530
2.855
PALI is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.8001.990
52 wk Range
0.5302.855
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PALI Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
9.714
Upside
+439.68%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
- Form DEF 14A PALISADE BIO For: 29 April
- Investing.com
- Form DEF 14A PALISADE BIO For: 29 April
- Investing.com
- Form PRE 14A PALISADE BIO For: 17 April
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 9.714
(+439.68% Upside)
Earnings
Latest Release
20-03-2026
EPS / Forecast
-0.04 / -0.27
Revenue / Forecast
-- / --
Compare PALI to Peers and Sector
Metrics to compare | PALI | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPALIPeersSector | |
|---|---|---|---|---|
P/E Ratio | −18.0x | −2.4x | −0.5x | |
PEG Ratio | −0.21 | −0.09 | 0.00 | |
Price/Book | 2.3x | 3.8x | 2.6x | |
Price / LTM Sales | - | 33.6x | 3.2x | |
Upside (Analyst Target) | 250.0% | 92.3% | 47.8% | |
Fair Value Upside | Unlock | 7.3% | 5.9% | Unlock |
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Palisade Bio (PALI) Share Price Today?
The Palisade Bio share price today is 1.800.
What is the current Palisade Bio (PALI) share price and day range?
As of 09-05-2026, the Palisade Bio share price is 1.800, with a previous close of 1.990. The share price has ranged from 1.800 to 1.990 today, while the 52-week range spans from 0.530 to 2.855.
What Is the Palisade Bio Market Cap?
As of today, Palisade Bio market cap is 301.360M.
What Is the Palisade Bio (PALI) Share Price Target?
The average 12-month share price target for Palisade Bio is 9.714, with a high estimate of 25 and a low estimate of 5. 7 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +439.68% Upside potential.
What Is Palisade Bio's Earnings Per Share (TTM)?
The Palisade Bio EPS (TTM) is -0.301.
From a Technical Analysis Perspective, Is PALI a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does Palisade Bio Trade On?
Palisade Bio is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Palisade Bio?
The stock symbol for Palisade Bio is "PALI."
How Many Times Has Palisade Bio Stock Split?
Palisade Bio has split 5 times.
How Many Employees Does Palisade Bio Have?
Palisade Bio has 14 employees.
What Is the PALI Premarket Price?
PALI's last pre-market stock price is 1.966. The pre-market share volume is 9,770.000, and the stock has changed by -0.024, or -1.210%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.